Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by Redbaron2211on Apr 21, 2021 12:43am
160 Views
Post# 33034954

RE:RE:RE:RE:RE:AGM = June 30

RE:RE:RE:RE:RE:AGM = June 30Fair enough, to be honest many of your thoughts are insightful and hold some merit.  We have basically discussed them all. I can try to elaborate but I also see some positives that don't get discussed like the investor deck that is still getting over 1k views a day on its way to 40k views or the way this has been trading since June you shouldn't dismiss the possibility that this is just an intermediate correction/consolidation on the way to a major win despite the obvious lack of business accume.  It appears that the main difference between us is that I believe the science is strong enough to make up for the shortcomings on the business side and Philip will continue to redeem himself.  

I haven't discounted Canaccord they may be waiting on timing to release something, everyone is super busy these days.  Other institutions may be accumulating or waiting on more data hard to know but future catalysts that help derisk could very easily initiate more institutional investment as we progress to phase 3.  
 
As for the markets no one is expecting anything more then a routine correction.  The last crash/recession was confirmed as the shortest in history.  I believe we are likely to see continued optimism as the population becomes vaccinated and the economy opens back up. With the ultra supportive fiscal and monetary policy its likely to lead to inflation / stagflation rather than a major downward acceleration.  Not saying there won't be corrections but they have little effect on the SP. 
 
Anyways count me in if Philip doesn't redeem himself.  I personally would like to see pressure to build a team regardless.  The CEO doesn't need to be a CDO, he just needs to hire a good one and then he can focus on the science that's fine by me.    
<< Previous
Bullboard Posts
Next >>